Literature DB >> 7198606

Retrovirus particle production in three of four human teratocarcinoma cell lines.

J Löwer, R Löwer, J Stegmann, H Frank, R Kurth.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7198606     DOI: 10.1007/978-3-642-67984-1_101

Source DB:  PubMed          Journal:  Haematol Blood Transfus        ISSN: 0171-7111


× No keyword cloud information.
  5 in total

1.  The transmembrane protein of the human endogenous retrovirus--K (HERV-K) modulates cytokine release and gene expression.

Authors:  Vladimir A Morozov; Viet Loan Dao Thi; Joachim Denner
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

2.  Identification of late assembly domains of the human endogenous retrovirus-K(HML-2).

Authors:  Claudia Chudak; Nadine Beimforde; Maja George; Anja Zimmermann; Veronika Lausch; Kirsten Hanke; Norbert Bannert
Journal:  Retrovirology       Date:  2013-11-19       Impact factor: 4.602

3.  The HERV-K accessory protein Np9 controls viability and migration of teratocarcinoma cells.

Authors:  Susana M Chan; Tamar Sapir; Sung-Soo Park; Jean-François Rual; Rafael Contreras-Galindo; Orly Reiner; David M Markovitz
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

4.  Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection.

Authors:  Mark H Kaplan; Mark Kaminski; Judith M Estes; Scott D Gitlin; Joseph Zahn; James T Elder; Trilokraj Tejasvi; Elizabeth Gensterblum; Amr H Sawalha; Joseph Patrick McGowan; Michael H Dosik; Haner Direskeneli; Guher Saruhan Direskeneli; Sally N Adebamowo; Clement A Adebamowo; Mohammad Sajadi; Rafael Contreras-Galindo
Journal:  BMC Med Genomics       Date:  2019-05-02       Impact factor: 3.063

5.  Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat.

Authors:  E H Richards; J A Hickman; J R Masters
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.